Articles tagged with Pancreatic Tumors
Researchers discovered that myeloid cells switch roles and become anti-therapy agents when angiogenesis inhibitors are used, leading to tumor growth and relapse. Targeting the PI3K signaling pathway may offer a way to prevent this phenomenon.
Researchers have found that cooperation between cancer cells leads to the evolution of resistance and relapses after therapy. A new treatment approach involves genetically modifying cancer cells to remove growth factor-producing genes, potentially eliminating tumor heterogeneity.
Researchers at Penn Medicine have discovered a mutated ATRX gene as a potential biomarker for aggressive brain tumors and rare adrenal tumors. The study found that 13% of tumors had ATRX mutations, which were more common in clinically aggressive cases.
High levels of miR-21 in tumor stroma and epithelia are associated with poorer clinical outcomes in triple-negative breast cancer. The study found that changes in the tumor microenvironment play a crucial role in determining disease progression.
A new computational model developed at Princeton University may help understand tumor dormancy, a phenomenon that can last up to 25 years in pancreatic cancer. The model predicts that tumors are likely to grow rapidly when the number of dividing cells reaches a certain critical level.
Researchers identified a tumor vessel-specific protein, L1, as a potential therapeutic target to reduce tumor growth and metastasis. Loss of L1 in mouse pancreatic cancer models reduced tumor angiogenesis and promoted vessel normalization.
Researchers at IMIM have identified galectin-1 as a potential therapeutic target for pancreatic cancer, demonstrating improved survival rates of 20% in mice. The inhibition of this protein mainly affects the immune system and surrounding tumor cells, suggesting a new strategy for treating pancreatic cancer with minimal side effects.
Pancreatic cancer tumors rely on Yap1 when mutant Kras is blocked, fueling tumor recurrence. Researchers found that Yap1-driven tumors resemble a poor-prognosis subtype of pancreatic cancer.
Researchers have discovered a unique molecular signature for adenosquamous carcinoma (ASC), a rare and virulent form of pancreatic cancer. The identification of somatic mutations in the UPF1 gene may lead to the development of novel diagnostic approaches and therapeutic strategies, offering new hope for patients with ASC.
Fibrous tissue in pancreatic tumors actually supports an immune attack that slows tumor progression but cannot overcome it. Immunotherapy could be a promising new avenue for guiding treatment, offering hope for patients with low levels of fibrosis in their tumors.
Researchers have found that eliminating scar tissue and inflammation in pancreatic cancer tumors can actually make them more deadly. In a new study, mice without desmoplasia developed tumors earlier and died sooner, suggesting that treatments targeting this complex scar tissue may need to be reevaluated.
Researchers at CNIO developed a new strategy to personalize cancer therapies for advanced patients by analyzing genetic mutations and testing drugs in 'Avatar' mice. The study showed clinical responses in up to 77% of patients, providing a promising approach for personalized medicine.
Researchers found that epigenetic alterations play a crucial role in disrupting intestinal T cell homeostasis, leading to autoimmune diseases like inflammatory bowel disease. A novel conditionally immortalized human β cell line has also been developed, offering new avenues for studying β cell properties and proliferation.
Researchers found that CT scans can predict chemotherapy effectiveness by analyzing tumor density and contrast uptake. This breakthrough could lead to personalized treatment plans for patients with pancreatic cancer.
Researchers have eradicated solid tumors in laboratory mice using a novel combination of two targeted agents that stimulate an immune response. This approach allows the patient's own tumor to act as a cancer vaccine, differing from traditional methods where the immune system is stimulated by administering a vaccine.
A new cancer vaccine has demonstrated prolonged survival in animal models of both tumors by stimulating the immune system to attack cancer cells. The vaccine combines a molecule targeting a tumor-cell-surface antigen with another protein that stimulates several immune functions.
Researchers at the Fred Hutchinson Cancer Center have found that removing immune suppressor cells from pancreas tumors triggers a spontaneous anti-tumor immune response, providing hope for future immunotherapy strategies. The study showed that these cells, called granulocyte-myeloid-derived suppressor cells (Gr-MDSCs), actively work ag...
VIB researchers have identified a protein, Nrp1, that suppresses the anti-tumor activity of macrophages. Blocking Nrp1 restores this immune response, leading to reduced tumor growth and improved prognosis.
Researchers discovered the recurrent T372R mutation in YY1 transcription factor is associated with insulinoma oncogenesis, suggesting a potential marker for diagnosis and treatment. The study found that 31 out of 103 cases had the T372R mutation, which enhances YY1's transcriptional activity.
EPFL researchers found that copper is essential for malignant cell energy production and that reducing its intake can slow down tumor growth. Copper deficiency resulted in lower respiration enzyme activity and increased glycolysis in tumors.
Losartan opens up collapsed tumor blood vessels, improving chemotherapy delivery and oxygenation. Combining losartan with standard treatments delays tumor growth and extends survival in animal models.
Researchers at Penn Medicine have developed a novel immunotherapy approach that demonstrates substantial tumor regression in patients with advanced pancreatic cancer. The treatment combines gemcitabine with an agonist CD40 antibody and uses real-time FDG/PET-CT imaging to monitor tumor response.
Researchers used nanosensors and advanced imaging techniques to track the spread of pancreatic tumors and monitor the effectiveness of drugs. The study reveals promising results for combination therapies that can enhance drug delivery and improve clinical outcomes.
A multi-institutional registry study involving 450 patients found that PRRT treatment significantly prolonged overall survival, with median progression-free survival of up to 51 months. Patients with pancreatic tumors survived an average of 39 months without disease progression.
A new electrical pulse treatment called irreversible electroporation (IRE) has been shown to be safe and effective for treating complex cancers without harming healthy tissue. IRE precisely perforates cancer cells, posing fewer risks to vital structures.
Two Indiana University researchers, Mark R. Kelley and Melissa L. Fishel, receive a $3.2 million grant to develop new therapies for pancreatic cancer. They aim to block a protein called Ref-1, which is involved in signaling between the tumor and its environment.
A preclinical study uses ultrasonic molecular imaging and Dynamic Contrast Enhanced-Perfusion Imaging to measure response to pancreatic cancer therapy. The study reveals that these new technologies can detect molecular signs of tumor response after just 2 days, improving the early identification of therapeutic response.
Researchers at Karolinska Institutet discovered that a deficiency in the endoglin protein weakens tumor blood vessels, allowing cancer cells to spread more easily. This finding suggests that strengthening blood vessel protective function may prevent cancer spread.
Researchers at MGH have identified components responsible for therapy-blocking solid stress and suggest therapeutic strategies. By measuring solid stress in tumor tissues, they found that inhibition of fibroblast growth can reduce solid stress and open up compressed blood vessels, improving treatment outcomes.
A Mayo-led study finds that pancreatic cancer develops from the interaction of KRAS mutations, inflammation, and epidermal growth factor receptor (EGFR), requiring multiple genetic factors for tumor formation. The study suggests that EGFR inhibitors may be effective in treating patients with chronic pancreatitis or normal p53 activity.
A new treatment protocol that includes accurate CT scan analysis and complex surgical technique has significantly increased long-term survival for patients with previously inoperable pancreatic adenocarcinoma. On average, patients lived about 30 months after tumor removal, nearly three times longer than those who never underwent surgery.
Studies using specialized MRI scans show that the procedure can detect whether anti-cancer chemotherapy is working, buying patients many months to a year of life. The scans use software to analyze water movement in tumor cells, identifying those with high and low apparent diffusion coefficients.
A novel chemotherapeutic agent, BAY 86-9766, has shown dramatic tumor shrinkage and prolonged survival in a genetically engineered mouse model of pancreatic ductal adenocarcinoma. The treatment was effective even in animals with advanced tumors and ascites, a common presentation in humans.
Researchers found that combining TH-302 with radiation reduced tumor growth in high and medium hypoxic xenografts, but not in low- or nonhypoxic implants. Tumor growth rates were also crucial in predicting treatment efficacy.
Researchers discovered that mutant Kras manipulates metabolic pathways to support tumor growth and progression in pancreatic cancer. The study found that turning off the oncogene caused tumors to regress and metabolic changes correlated with gene expression changes.
Researchers have made significant advancements in treating autoimmune diabetes by harnessing the power of gut bacteria. Additionally, studies on cancer treatment and tumor growth have revealed that vascular normalization can prevent dangerous side effects while enhancing anti-tumor effects. Furthermore, scientists have discovered a coo...
Researchers validated two new staging classification systems for neuroendocrine pancreatic tumors, finding that advancing stage correlates with increasing risk of metastatic relapse after surgery. The study also showed that small, low-grade tumors have exceptionally low metastatic potential.
Researchers found that activating a cholesterol pathway may enhance chemotherapy's effectiveness against pancreatic cancer. The study used a cholesterol derivative to block the Hedgehog pathway, which is linked to both cancer and heart disease.
Researchers found success with irreversible electroporation to treat primary and metastatic liver cancer; the technique is now being implemented as a treatment for pancreatic cancer. Two out of eight participants had successful resections after IRE, with improved survival rates compared to traditional treatments.
Researchers at Fred Hutchinson Cancer Center have discovered a way to break down the biological barrier surrounding pancreas cancer tumors, allowing chemotherapy to penetrate and increase survival rates. The new approach shows significant promise for treating this deadly disease.
Dual inhibition of VEGF and c-MET signaling inhibits tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer. Inhibition of VEGF alone increases c-MET expression, leading to increased invasiveness and metastasis.
A mutant protein in nearly all pancreatic cancers plays a role in its development and continued growth, according to a U-M study. Inactivating Kras eliminated tumors in mice, but left fibrous areas similar to scar tissue, suggesting possible treatment targets.
Researchers have discovered a new target for cancer therapy, TDO enzyme, which enables tumors to evade immune rejection. A novel inhibitor of TDO has shown promising results in preclinical studies.
Five scientists have been awarded $2.25 million to develop innovative approaches to fighting cancer, including targeting macrophages and biomarkers. The grants aim to improve the prevention, diagnosis, and treatment of cancer.
Researchers have identified a new reprogramming mechanism for tumor cells, with the protein CPEB4 activating hundreds of genes associated with tumor growth. The study found that inhibition of CPEB4 reduces tumor size by up to 80%, providing a promising avenue for new cancer treatments.
Researchers found that free radical peroxynitrite is produced by myeloid cells in tumors and interferes with the immune system's ability to kill cancer cells. This mechanism may explain why some cancer immunotherapies fail to work, allowing tumors to evade immune detection.
A study on mice shows that reducing IRS2 signaling can slow the progression of Huntington disease. Meanwhile, research also finds that circulating glucose levels can modulate neural control of desire for high-calorie foods in humans. These findings provide potential therapeutic targets and new insights into the biology of obesity.
Researchers have discovered that the vaccinia virus construct GLV-1h153 can be used to image and treat pancreatic cancer. The study found that hNIS-mediated radiouptake noninvasively imaged with PET provided information into tumor therapeutic response.
Tiny oxygen generators implanted in tumors boost killing power of radiation and chemotherapy, treating hypoxic solid tumors. The technology has shown promising results in shrinking tumors faster than those without devices.
A prospective cohort study found that a tumor marker and targeted endoscopic ultrasound can detect stage 1 pancreatic cancer in high-risk populations more effectively than standard means of detection. The study identified a total of one patient with stage 1 disease among 546 enrolled participants.
Two new studies published in Annals of Internal Medicine explore treatments for older adults with chronic obstructive pulmonary disease (COPD) and patients with severe allergic asthma. Long-acting inhaled beta-agonists were found to increase survival rates over anticholinergics, while omalizumab improved symptoms and quality-of-life sc...
The American Association for Cancer Research has awarded grants to researchers studying carcinoid tumors and pancreatic neuroendocrine tumors. These grants will support the development of new treatments and therapies for these cancers, including those targeting the menin-regulated signaling pathway and oncolytic viral therapy.
Researchers at the University of Pennsylvania have discovered a novel way to treat pancreatic cancer by activating the immune system to destroy the cancer's scaffolding. The strategy was tested in a small cohort of patients with advanced pancreatic cancer, resulting in substantial tumor shrinkage and reduced metabolic activity.
Researchers identify thymic stromal lymphopoietin (TSLP) as a key driver of Th2 inflammation in human breast and pancreatic tumors. TSLP from cancer cells or fibroblasts fuels Th2 inflammation, promoting tumor growth.
A Phase III trial found that everolimus significantly improved progression-free survival for patients with advanced pancreatic neuroendocrine tumors, reducing the risk by 65% and increasing median progression-free survival by over six months. Common side effects include stomatitis, rash, diarrhea, fatigue, and infections.
Researchers at Thomas Jefferson University developed a new real-time tumor tracking technique that minimizes radiation delivery to surrounding healthy tissue by up to 50%. This approach enables radiation oncologists to administer more radiation and faster to tumors, potentially decreasing side effects.
Researchers discovered that breast cancer cells release heat shock protein 27 (Hsp27), which renders immune cells unresponsive and fuels tumor growth. This finding provides a new treatment target in the fight against breast cancer.
Researchers identified specific genetic mutations that predict tumor aggressiveness and treatment response in patients with neuroendocrine pancreatic cancer. The study's findings could lead to personalized cancer therapy and improved patient outcomes.
Researchers at Johns Hopkins Medicine discovered a potential therapy strategy by restoring lost microRNAs in human pancreatic tumor cells. The study found that these microRNAs put brakes on tumors when the KRAS gene is mutated, a common event in pancreatic cancer.
A new study found that many pancreatic tumors are slow-growing, taking nearly 20 years to become lethal after the first genetic perturbations appear. This challenges previous theories and suggests a potential window of opportunity for early diagnosis and treatment.